| MDLZ |
Report |
Organic Revenue Growth (Q2 2026) |
BEAT |
pred ~+2.5% vs. cons +0.75% |
MEDIUM |
| MDLZ |
Report |
Volume/Mix (Q2 2026) |
BEAT |
pred ~-0.3% vs. cons -1.24% |
MEDIUM |
| MDLZ |
Report |
Adj. EPS Diluted (Q2 2026) |
BEAT |
pred ~$0.71 vs. cons $0.679 |
MEDIUM |
| MDLZ |
Guide |
FY 2026 Organic Revenue Growth (FY2026) |
UNCHANGED |
guide ~mid +1.75% vs. cons +1.74% |
MEDIUM |
| MDLZ |
Guide |
FY 2026 Adj. EPS Growth (FY2026) |
LOWER |
guide top ~5% (implied ~$2.94) vs. cons $3.045 |
MEDIUM |
| MDLZ |
Guide |
FY 2026 Free Cash Flow (FY2026) |
LOWER |
guide reaffirm ~$3.0B vs. cons $3.24B |
MEDIUM |
| MDLZ |
Guide |
Volume/Mix Trajectory (qualitative, H2 2026) |
BETTER |
confirm H2 volume positive vs. cons ~flat |
MEDIUM |
| MDLZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| MDLZ |
Return |
5-day cumulative residual |
+1.0% (FADE) |
FADE — EPS estimate cuts post-print partially reverse the initial beat reaction as sell-side models the EPS guide top-of-range below consensus |
MEDIUM |